U.S., June 18 -- ClinicalTrials.gov registry received information related to the study (NCT07654829) titled 'Safety and Effectiveness of Sebetralstat for Short-Term Prevention Before Procedures in People With Hereditary Angioedema' on June 12.
Brief Summary: This is a Phase 4, prospective, open-label trial to evaluate the safety and effectiveness of sebetralstat when used for STP for a qualifying procedures in patients 12 years of age or older with hereditary angioedema (HAE).
Study Start Date: June 15
Study Type: INTERVENTIONAL
Condition:
Hereditary Angioedema
Intervention:
DRUG: KVD900 600 mg
KVD900 Tablet 600 mg (2 x 300 mg)
Recruitment Status: NOT_YET_RECRUITING
Sponsor: KalVista Pharmaceuticals, Ltd.
Published by HT Digital ...